Four weeks after bilateral nerve-sparing radical retropubic prostatectomy, men with normal erectile function before surgery were randomized to double-blind sildenafil (50 or 100 mg) or placebo nightly for 36 weeks, followed by an 8-week drug-free period before assessment of erectile function. Enrollment was prematurely ceased and only 76 men completed because, assuming a placebo response rate similar to the published literature (for example, 34% in meta-analysis), the 25% response at blinded interim review suggested a lack of treatment effect. On the contrary, spontaneous erectile function (a combined score of X8 for questions 3 and 4 of the International Index of Erectile Function and a positive response to 'Were erections good enough for satisfactory sexual activity?') occurred in only 4% of the placebo group (n ¼ 1 of 25) versus 27% (n ¼ 14 of 51, P ¼ 0.0156, Fisher's exact test) of the sildenafil group. Nightly sildenafil administration for 36 weeks after surgery markedly increased the return of normal spontaneous erections.
Introduction
Erectile dysfunction (ED) after bilateral nerve-sparing radical prostatectomy may be related to multiple factors, such as the age of the patient, preoperative erectile function and the experience of the surgeon. 1 Anatomically, the small size of the cavernous nerves precludes clear visualization during surgery, making them susceptible to intraoperative trauma and damage. 2 Even spared nerves can experience neurapraxia, a temporary failure in nerve conduction resulting from insult. Neurapraxia may explain temporary (short-term) ED following nerve-sparing prostatectomy. Sustained ED is more likely to be caused by secondary cavernosal trabecular smooth muscle apoptosis and its replacement with collagen. 3, 4 Post-prostatectomy ED is severe and may include loss of nocturnal erections, and recovery is slower than generally reported in the literature; many men will not regain erectile function for more than 12 months. 1 ED after prostatectomy is generally treated symptomatically, as needed when intercourse is anticipated. 5, 6 However, early regular use of intracavernosal alprostadil injections, in an uncontrolled study, has been shown to improve the recovery rate of spontaneous erections after nerve-sparing radical retropubic prostatectomy. 7 Despite this benefit, pain, complications and inconvenience detract from the willingness of patients to use intracavernosal injections regularly.
Early, regular (every other night) use of sildenafil citrate (Viagra; Pfizer Inc, New York, NY, USA) after nerve-sparing radical retropubic prostatectomy has been shown, in an uncontrolled human study, to preserve or increase intracorporeal smooth muscle content. 8 Moreover, sildenafil taken at bedtime has been shown to significantly improve nocturnal erectile activity in men with vasculogenic or psychogenic ED, 9 indicating vascular effects mediated by release of cavernous nerve nitric oxide during rapid eye movement and phase 4 sleep. Indeed, since the inception of the current study, it has become common clinical practice to provide sildenafil postoperatively for variable periods of time. For example, in a study of 167 men who were potent before bilateral nerve-sparing radical retropubic prostatectomy, approximately half used sildenafil on an on-demand basis as needed for the symptomatic treatment of ED; recently reported 4-year follow-up data from this study have shown a continuing improvement in erectile function with time. 10 The current study provides, for the first time, objective data and a protocol for the use of sildenafil after nerve-sparing prostatectomy. The objective was to evaluate the efficacy of prophylactic, nightly use of sildenafil in preventing long-term ED. A second objective was to investigate the potential mechanism of action of sildenafil in preventing long-term ED by evaluating its effects on nocturnal penile erections.
Materials and methods

Study design
This study was designed to be a randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study conducted in three phases between April 1999 and October 2001 at outpatient urology clinics. A total of 16 sites in North America, France, Belgium and Australia screened patients, and 11 sites in North America and France enrolled and randomized patients.
During the 1-to 4-week preoperative assessment (phase 1), all patients underwent baseline evaluation of their erectile function using the International Index of Erectile Function. 11 A subgroup, consisting of all men enrolled at two sites, also underwent evaluation of nocturnal penile tumescence and rigidity at home (2 consecutive nights) using penile plethysmography (RigiScan; Timm Medical Technologies, Eden Prairie, MN, USA). At 4 weeks after surgery, patients entered the 36-week double-blind, postoperative treatment (phase 2) during which 50-or 100-mg sildenafil, or matching placebo, was taken once daily at nighttime. Erectile function was assessed, and plethysmography was conducted in the subgroup, after 12, 24 and 36 weeks of treatment. When double-blind treatment was discontinued, patients remained untreated for 8 weeks (phase 3); no ED therapy, including sildenafil, was permitted. At the end of this period, erectile function, and nocturnal penile tumescence and rigidity in the subgroup, was assessed.
Computer-generated randomization was in a 1:1:1 ratio using the method of random permuted blocks and a pseudorandom number generator. Eligible patients were allocated a randomization number at the first visit of phase 2. Tablets containing 50-or 100-mg sildenafil or matching placebo were supplied to the investigators in blister cards in a double-dummy fashion.
Institutional Review Board/independent Ethics Committee approval was obtained at all study sites, and signed informed consent was obtained from all participants.
Patients
Eligible men were 18-70 years of age, weighing 50-125 kg, and scheduled to undergo bilateral nerve-sparing radical retropubic prostatectomy by experienced surgeons. Patients had to have normal preoperative erectile function, wish to return to sexual activity after surgery and be in a stable, heterosexual relationship for the past 6 months. Normal preoperative erectile function was defined as a combined score of at least 8 on questions 3 and 4 of the International Index of Erectile Function (Q3: 'Over the past 4 weeks, when you attempted sexual intercourse, how often were you able to penetrate your partner?'; Q4: 'Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?'). Individual scores for these questions were 0 ('Did not attempt intercourse'), 1 ('Almost never/never'), 2 ('A few times (much less than half the time)'), 3 ('Sometimes (about half the time)'), 4 ('Most times (much more than half the time)') and 5 ('Almost always/always').
For the subgroup undergoing plethysmography, an additional inclusion criterion was normal penile tumescence and rigidity, defined as X55% base rigidity for 10 consecutive minutes on at least 1 of 2 consecutive nights of monitoring before surgery.
Patients were excluded if they had pathological stage greater than PT2, a tumor Gleason score equal to or greater than 8 on a preoperative biopsy, prostatespecific antigen levels equal to or greater than 20 mg l À1 , positive lymph nodes or required postoperative radiation or androgen ablation therapy. Patients were also excluded if they had a sleep disorder, were taking sedative/hypnotics as sleep aids or were receiving nitrates or any treatment for ED.
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Efficacy measures
The primary measure was the percentage of patients who were responders. A stringent responder definition was established a priori as those patients who, at the end of phase 3, had a combined score of at least 8 for Q3 and Q4 of the International Index of Erectile Function, and also answered 'yes' to the question, 'Over the past 4 weeks, have your erections been good enough for satisfactory sexual activity?' Secondary measures were changes from baseline in the six-item Erectile Function domain of the International Index of Erectile Function and, for the plethysmography subgroup, the duration of penile tumescence and rigidity. The Erectile Function domain has a score range of 1-30, with ED graded as severe (1-10), moderate (11) (12) (13) (14) (15) (16) , mild to moderate (17-21), mild (22) (23) (24) (25) and none (26) (27) (28) (29) (30) . 12 
Statistics
On the basis of analyses of Q3 and Q4 of the International Index of Erectile Function in previous studies, a conservative standard deviation of 2.00 was assumed. If the mean sildenafil versus placebo difference for at least one of the sildenafil groups was 1.5 points for both variables, then a sample size of 44 patients per treatment group would provide 90% power to detect a significant difference between variables singly and 80% power to detect significant differences for both variables jointly, based on two-sided analysis of variance tests conducted at the 0.05 significance level with Dunnett's adjustment. Assuming that 80% of randomized patients would contribute to the intent-to-treat analyses, a sample size of 55 patients per treatment group was required. However, enrollment ceased after 125 because an interim blinded review of data from the 35 completed patients showed a response rate of only 25% (9 of 35), which was not what was expected based on rates of spontaneous recovery of erectile function reported in the published literature. [13] [14] [15] [16] [17] After enrollment ceased, two US study centers remained active to complete all the study visits in the ongoing patients in the plethysmography subgroup and to provide information to aid in planning possible future studies.
All statistical analyses were performed using Statistical Analysis System software version 6.12 for efficacy analyses and version 8.2 for demographic and safety analyses. Primary and secondary efficacy variables were analyzed in patients who completed the 36-week double-blind treatment period and the 8-week drug-free evaluation period. In the original statistical analysis plan, the primary efficacy measure (percentage of responders) was to be analyzed using the pair-wise CochranMantel-Haenszel (CMH) test. However, because the Mantel-Fleiss criterion was not satisfied, the CMH test was determined to be inappropriate for analysis purposes. Therefore, Fisher's exact test (two-tailed) was used as an alternative (and appropriate for the existing number of patients) approach, with the Bonferroni adjustment to account for multiple comparisons with placebo. Secondary efficacy measures were analyzed using the nonparametric Wilcoxon rank-sum test. Safety was assessed in patients who took at least one dose of study medication.
Results
Of 238 patients screened, 125 were randomized to treatment and 123 received at least one dose of study drug. In total, 94% (117 of 125) of the randomized patients were enrolled at five North American sites. Patients were largely similar among treatment groups with respect to demographics ( Table 1) . Across the groups, a similar number of patients a One additional patient was randomized to this group, but discontinued before receiving study drug.
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The 36-week double-blind treatment period was completed by 82 men. The subsequent 8-week drug-free evaluation period was completed by 76 men, who constituted the population analyzed for efficacy: placebo, n ¼ 25; sildenafil 50 mg, n ¼ 23; sildenafil 100 mg, n ¼ 28. Of these 76 men, 54 were enrolled at the two US study centers, which remained active to complete all the study visits in ongoing patients, and were included in the plethysmography subgroup. The other 22 men were enrolled at three other North American study centers. The eight men randomized at the other six study centers were discontinued prematurely when the centers were terminated after the interim review. Reasons for the 47 premature discontinuations in the placebo, sildenafil 50-mg, and sildenafil 100-mg treatment groups, respectively, were lack of efficacy (n ¼ 3, 2 and 1); adverse events (n ¼ 1, 5 and 1); loss to follow-up, withdrawn consent, noncompliance, loss of stable sexual partner or protocol violation (n ¼ 7, 2 and 6) and study closure (n ¼ 6, 8 and 5). Demographics were largely similar among treatment groups in the analyzed population, and between the analyzed population and the larger population of patients who took study drug (Table 1) .
Primary efficacy results: percentage of responders
At 48 weeks after undergoing prostatectomy (that is, 8 weeks after discontinuation of drug treatment), 15 of 76 patients were categorized as responders (20%), including 6 of 23 in the sildenafil 50 mg group (26%), 8 of 28 in the sildenafil 100 mg group (29%) and 1 of 25 in the placebo group (4%); overall, 14 of 51 patients who completed sildenafil treatment were responders (27%; Table 2 ). An additional four patients treated with sildenafil had a combined score of at least 4 for Q3 and Q4 of the International Index of Erectile Function, indicating that partial erectile function was achieved.
Secondary efficacy results: erectile function domain
Erectile Function domain scores were reported as mean ± s.d. (median). Before surgery, scores were 28.8 ± 1.6 (30) in the sildenafil group and 28.6 ± 2.2 (30) in the placebo group, indicating no ED. Endof-study scores were 13.1±9.5 (9) in the men who had used sildenafil during the treatment phase, including 12.4±9.2 (9) in the 50-mg group and 13.7±9.8 (10) in the 100-mg group, compared with 8.8 ± 7.0 (6), in those who had used placebo during the treatment phase. More importantly, the endof-study scores for the responders to sildenafil treatment were 26.9 ± 2.2 (27), including 26.3 ± 1.9 (27) in the 50-mg group and 27.3±2.5 (28) in the 100-mg group; for the one patient who responded to placebo, the score was 23.
Secondary efficacy results: nocturnal penile rigidity
Of the 54 men who underwent RigiScan assessment, 35 were randomized to sildenafil treatment. Prior to surgery, nocturnal penile rigidity at the base of the penis was similar between sildenafil responders (n ¼ 10) and nonresponders (n ¼ 25); (median: 59 and 65 min, respectively). Median duration of nocturnal penile rigidity was markedly reduced to less than 1 min in both sildenafil responders and nonresponders, 4 weeks post-surgery. At 48 weeks after prostatectomy, and 8 weeks after discontinuation of drug treatment, sildenafil responders had a longer duration of base rigidity (median: 6 min) than nonresponders (median: 1 min) (Figure 1 ).
Safety
Nightly use of sildenafil was well tolerated ( Table 3) . The most commonly reported adverse events were dyspepsia, headache, flushing, abnormal vision and rhinitis. Most adverse events were transient and mild in nature; two patients in the 50-mg sildenafil group discontinued because of treatment-related adverse events. Although six serious adverse events were reported, none of these were related to study drug.
Discussion
In a small but representative sample, we have demonstrated that nightly administration of sildenafil Sildenafil and ED after radical prostatectomy H Padma-Nathan et al for 9 months, beginning 1 month after bilateral nerve-sparing radical retropubic prostatectomy, resulted in the return of spontaneous erections in 27% (n ¼ 14 of 51) of men, compared with only 4% (n ¼ 1 of 25) of men receiving placebo. These results were observed at the end of an 8-week drug-free period (1 year post-surgery) and were supported by Erectile Function domain scores and by nocturnal penile plethysmography. The similar response rate between the 50-and 100-mg doses of sildenafil suggests future study to identify the minimally effective dose.
The study results reveal that the majority of men who undergo bilateral nerve-sparing radical retropubic prostatectomy have ED a year later. Because we assumed a placebo response rate similar to that of the published literature (see below), the low overall response rate (25% (9 of 35) ) at the blinded interim review suggested a lack of treatment effect and resulted in a decision to prematurely cease enrollment. Most discontinuations were because of study closure (n ¼ 19). Although prematurely ceasing enrollment and closing study sites precluded achieving the original sample size goal, the treatment assignment followed the original randomization ratio. Given the ultimate number of patients, use of Fisher's exact test (two-tailed), with the Bonferroni adjustment to account for multiple comparisons with placebo, was an appropriate alternative statistical test to the originally planned statistical analysis. However, the results should be interpreted in the context of patients actually completing the prescribed therapy.
Nightly sildenafil was well tolerated: only two patients, both in the sildenafil 50-mg group, discontinued the study because of adverse events related to sildenafil treatment. Six patients discontinued prematurely because of lack of efficacy, suggesting a misunderstanding of the study objective: the prevention of long-term ED following prostatectomy.
The 4% rate of return for spontaneous erectile function in the placebo group (n ¼ 1 of 25) is considerably lower than was expected based on the published literature. There is a wide range of rates reported in the literature, with the variation being attributed to patient age, preoperative sexual function, time since surgery, nerve-sparing procedure, surgeon experience and reporter bias. 13, 14 For example, in two large series of preoperatively potent men who underwent nerve-sparing prostatectomy (most frequently bilateral nerve-sparing), recovery of erections occurred in approximately two-thirds (571 of 858 15 and 342 of 503 2 ); the recovery rate was inversely related to age at surgery. In contrast, in a series of 1072 Medicare patients, mostly consisting of older patients with lower rates of preoperative potency, only 11% had erections sufficient for intercourse following surgery. 16 In a meta-analysis of 14 studies conducted through 2001, including over 600 patients, the probability of maintaining erectile function was 34% (95% confidence interval (CI) 30-38%) within the year following nervesparing prostatectomy. 17 The discrepancy between the published literature and the results of the current study may reflect differences from our methodology, such as the absence of controls to (7) 2 (5) 1 (2) Patients with severe AEs, n (%) 3 (7) 2 (5) 1 (2) Patients discontinued due to AEs, n (%) b 1 (2) 5 (12) 1 (2) Most commonly occurring AEs (X2% of patients) Headache, n (%) 3 (7) 6 (15) 
Abbreviation: AE, adverse event. a None of the serious AEs were considered treatment related. b The only treatment-related AEs that were associated with patient discontinuation were mild fatigue, headache and dyspepsia in one patient treated with sildenafil 50 mg, and mild dyspepsia and severe headache in a second patient treated with sildenafil 50 mg.
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End of study Week 48   130  120  110  100  90  80  70  60  50  40  30  20 10 0 Figure 1 Nocturnal penile rigidity at the base of the penis as assessed using RigiScan, in responders (n ¼ 10) and nonresponders (n ¼ 25) to sildenafil treatment, before and 4 and 48 weeks after prostatectomy. Responders were a priori defined as those patients who, at the end of the 8-week drug-free period, had a combined score of at least 8 on Q3 and Q4 from the International Index of Erectile Function (scores for each question ranged from 0 to 5) and answered 'yes' to the question 'Over the past 4 weeks, have your erections been good enough for satisfactory sexual activity?' Data are shown as median and 25th to 75th percentile bars, with 10th and 90th percentile limits. Of the 54 men who underwent RigiScan assessment, 19 others were randomized to placebo.
Sildenafil and ED after radical prostatectomy H Padma-Nathan et al prevent bias, the use of nonvalidated questionnaires or a less stringent definition of responders. For example, in other studies the criteria for a positive response are often not well defined, lack details (that is, on the quality of erections (full versus partial rigidity)) and do not necessarily correspond to the ability to achieve sexual intercourse. In contrast to the published literature, we used a stringent definition of response. The requirement for a combined score of at least 8 for Q3 ('When you attempted sexual intercourse, how often were you able to penetrate your partner?') and Q4 ('During sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?') necessitated a response of 'Almost always/always' on Q3 and 'Sometimes (about half the time)' on Q4 or a response of 'Most times (much more than half the time)' on each question. Penetration and maintained erection are clinically meaningful to the patient because they are prerequisite to satisfactory sexual intercourse. In addition, we required an answer of 'yes' to the question, 'Over the past 4 weeks, have your erections been good enough for satisfactory sexual activity?' This stringent definition of response was attained by 27% (14 of 51) of the sildenafil group.
Because it is now common clinical practice to provide sildenafil on an on-demand basis for variable periods of time after prostatectomy as needed for the symptomatic treatment of ED, recent reports of post-prostatectomy potency often reflect this practice pattern. For example, approximately half of 167 men who were potent before bilateral nerve-sparing radical retropubic prostatectomy used sildenafil on-demand; recovery of normal erections, defined as a score of at least 26 on the Erectile Function domain of the International Index of Erectile Function, was achieved by 8% of patients after 12 months, compared with 51% after 48 months. 10 An on-demand study of sildenafil after nerve-sparing radical retropubic prostatectomy has demonstrated that treatment satisfaction peaked between 18 and 24 months. 13 These results suggest that further study is needed to determine the optimum timing and duration of sildenafil therapy.
The mechanism of action of sildenafil in preventing long-term ED following bilateral nerve-sparing radical retropubic prostatectomy remains unclear but is probably multifactorial. This is in keeping with the apparently multifactorial etiology of ED after prostatectomy, in which vascular factors appear to be important in some cases and neurogenic factors apparently play a major role. 18 This study clearly demonstrates the profound loss of nocturnal erections after surgery. Hypoxia may be involved in both temporary and permanent ED following prostatectomy. Hypoxia causes temporary ED by significantly reducing the synthesis and release of nitric oxide (the principal mediator of penile erection via the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway [19] [20] [21] ), thereby compromising the endothelium-dependent and neurogenic relaxation of corpus cavernosum smooth muscle. 22 Hypoxia can cause permanent ED by increasing synthesis of transforming growth factorb and endothelin, which ultimately leads to vasoconstriction and corporeal fibrosis. 7, 23 Sildenafil selectively inhibits phosphodiesterase type 5 and thereby prevents cGMP degradation, 24 compensating for the reduced availability of nitric oxide during hypoxia; this enhances smooth muscle relaxation of the corpus cavernosum, 25 promoting blood flow to the penis.
Sildenafil may have unique and more relevant mechanisms of action in preventing long-term ED after nerve-sparing prostatectomy. In patients with chronic heart failure, in whom vascular endothelial function (vasodilation) is impaired, administration of sildenafil improved endothelium-dependent vasodilation, as demonstrated by improved flowmediated vasodilation compared with placebo. 26, 27 Similarly, in patients with type 2 diabetes, low-dose sildenafil improved vascular endothelial function. 28 Also, phosphodiesterase 5 inhibitors have been shown to be neuroprotective to cultured spinal motor and nonmotor neurons, 29 and sildenafil increased neurogenesis and reduced neurological deficits in rats treated within 24 h of stroke. 30 Thus, therapeutic postoperative intervention with sildenafil may improve corpus cavernosum endothelial function and promote recovery of nerve function.
Conclusions
Even with nerve-sparing surgery, most men will have severe ED a year after prostatectomy, strongly suggesting the need for early primary prevention measures. This is the first long-term, prospective, blinded study that assessed prophylactic nightly dosing of sildenafil on recovery of erectile function after bilateral nerve-sparing radical retropubic prostatectomy. The failure to complete the study according to its initial power calculations, which were based on anticipated placebo response rates that did not hold true, does not negate the importance of the findings. Nightly administration of sildenafil for 36 weeks beginning 4 weeks after prostatectomy resulted in a marked restorative effect (an increase over placebo in ability to achieve spontaneous erection) 8 weeks after the end of sildenafil treatment. These results show that pharmacological intervention during the convalescent period can enhance the recovery of spontaneous erections, and provide objective data and a protocol for the now common clinical practice of providing sildenafil postoperatively for variable periods of time.
Prior to surgery, patients should be counseled about the realistic outcome and educated about the most effective treatment alternatives available to optimize the return of erectile function after surgery.
These data suggest that there is an advantage in initiating early primary prevention measures after bilateral nerve-sparing radical retropubic prostatectomy, and that more men may regain spontaneous erectile function when treated proactively with sildenafil. Follow-up studies are warranted to support the results of the current study and to examine the effect of lower doses, earlier initiation of therapy and intermittent therapy, and to determine the optimal duration of therapy. Other unanswered questions include the mechanism of action of sildenafil in preserving erectile function and whether sildenafil use results in better return of function, faster return of function or both.
